Thoracoabdominal Artery Stent Graft System Exploratory Study
Recruiting now · Not applicable
Conditions studied: Thoracoabdominal Aortic Aneurysms
In brief
This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).
Key facts
- Study ID
- NCT06710938
- Run by
- Lifetech Scientific (Shenzhen) Co., Ltd.
- People needed
- 11
- Starts
- 2025-07-24
- Expected to finish
- 2032-06-30
- Last updated by the study team
- 2026-05-26
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age: 18 to 80 years old;
- Patients diagnosed with a Thoracoabdominal aortic aneurysm (based on the modified Crawford classification and European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms), and should meet at least ONE of the following conditions:
- Maximum diameter of TAAA is >50 mm;
- TAAA diameter increases by more than 5 mm in the past 6 months or by more than 10 mm in the past 1 year;
- Definite symptoms associated with TAAA, such as abdominal pain and back pain.
- Anatomical Criteria
- Proximal landing zone (aorta or implanted graft): the diameter ranges from 17 to 36 mm, and length should be ≥25 mm;
- Distal landing zone (aorta or implanted graft): If distal landing zone is in iliac artery, distal landing zone diameter ranges from 7 to 25 mm, and length should be ≥15 mm; If the distal landing zone is in the abdominal aorta, distal landing zone diameter ranges from 12 to 36 mm, and length should be ≥20 mm.
- Visceral branch landing zone: the diameter ranges from 6 to 13 mm, and the length should be ≥15 mm;
- Renal artery landing zone: the diameter ranges from 4.5 to 9 mm, and the length should be ≥15 mm;
- Appropriate iliac, femoral, and upper limb arterial access.
- Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol;
- Patients do not want to or cannot wait for the approved alternative
You may not qualify if…
- Exclusion Criteria (not eligible if any of the criteria is met):
- Patients with ruptured thoracoabdominal aortic aneurysms in unstable hemodynamic condition;
- Patients with thoracoabdominal aortic dissection;
- Patients with infected or mycotic thoracoabdominal aortic aneurysms;
- Patients with systemic or local infections that may increase the risk of endovascular graft infection;
- Patients with occluded superior mesenteric artery, celiac trunk artery, or renal artery;
- Patients requiring simultaneous coverage or embolization of bilateral internal iliac arteries;
- Patients with severe stenosis, calcification or mural thrombus at stent-graft landing zone, and this situation leads to difficulty in adhering the covered stent or affecting the patency of the stent;
- Patients with a history of acute coronary syndrome within the recent 6 months; Acute coronary syndrome refers to acute cardiac ischemic syndrome caused by rupture or erosion of unstable atherosclerotic plaques in the coronary artery and fresh thrombosis, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris.
- Patients with transient ischemic attack (TIA) or ischemic/hemorrhagic stroke within the recent 3 months;
- Patients with abnormal liver and kidney function before operation [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal value; Serum creatinine (Cr) >150umol/L];
- Patients with severe pulmonary insufficiency who cannot tolerate general anesthesia;
Where it is running
- Asklepios Klinik Nord Heidberg — Hamburg, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.